Scott Blumberg Sells 846 Shares of CeriBell (NASDAQ:CBLL) Stock

Posted by Stanley Muller on Sep 19th, 2026

CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) CFO Scott Blumberg sold 846 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $25.00, for a total value of $21,150.00. Following the sale, the chief financial officer directly owned 146,600 shares in the company, valued at approximately $3,665,000. This represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Scott Blumberg also recently made the following trade(s):

On Wednesday, September 2nd, Scott Blumberg sold 652 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total transaction of $16,300.00.
On Friday, August 21st, Scott Blumberg sold 1,521 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total transaction of $36,534.42.
On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total transaction of $838,805.36.
On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total transaction of $24,750.00.

CeriBell Stock Performance

Shares of NASDAQ CBLL opened at $24.37 on Friday. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16. The firm’s 50-day moving average price is $21.61 and its two-hundred day moving average price is $19.82. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $25.63. The stock has a market capitalization of $935.32 million, a P/E ratio of -13.85 and a beta of 0.95.

CeriBell (NASDAQ:CBLL – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The company had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. As a group, sell-side analysts forecast that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Institutional Investors Weigh In On CeriBell

Several institutional investors have recently bought and sold shares of CBLL. Squarepoint Ops LLC bought a new position in CeriBell in the 2nd quarter valued at about $638,000. Wellington Management Group LLP lifted its stake in shares of CeriBell by 5.5% in the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after acquiring an additional 4,572 shares during the period. Formula Growth Ltd. bought a new position in shares of CeriBell in the second quarter valued at approximately $603,000. Bank of America Corp DE acquired a new position in shares of CeriBell during the second quarter valued at approximately $4,619,000. Finally, PDT Partners LLC acquired a new position in shares of CeriBell during the second quarter valued at approximately $1,026,000.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CBLL. BTIG Research restated a “buy” rating and set a $30.00 price target on shares of CeriBell in a research report on Friday, September 11th. Raymond James Financial reiterated a “strong-buy” rating and issued a $29.00 price objective on shares of CeriBell in a research report on Thursday, September 3rd. Barclays upgraded shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Finally, Canaccord Genuity Group boosted their price objective on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.40.

View Our Latest Research Report on CBLL

CeriBell Company Profile

(Get Free Report)

Ceribell, Inc (NASDAQ: CBLL) is a medical technology company focused on improving the detection and management of seizures and other neurological conditions in hospital settings. Its products are designed to make electroencephalography (EEG) more accessible at the point of care, particularly in emergency departments, intensive care units and other settings where conventional EEG testing may be delayed or difficult to obtain.

The company’s primary offering is the Ceribell Rapid Response EEG system, which combines a portable EEG recorder, a simplified electrode headband and software for acquiring and reviewing brain-wave data.